Considering the significance of immune checkpoint inhibitors (ICBs) in cancer immunotherapy, we also noted that LRG patients exhibited a significant upregulation in the expression of immune checkpoint genes, including HHLA2, CD2AP, CD9, IDO2, CD1A, CD1B, CD1E, CD24, CD47, and others. This evidence concerns the gene HHLA2 and cancer.